Thr733
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr733  -  ERK5 (human)

Site Information
LPPVFsGtPKGSGAG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 455520

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 3 ) , immunoassay ( 2 ) , immunoprecipitation ( 1 , 3 , 5 ) , mass spectrometry ( 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ) , mutation of modification site ( 1 , 11 ) , phospho-antibody ( 1 , 2 , 3 , 5 ) , western blotting ( 1 , 2 , 3 , 5 )
Disease tissue studied:
breast cancer ( 7 ) , breast ductal carcinoma ( 7 ) , HER2 positive breast cancer ( 4 ) , luminal A breast cancer ( 4 ) , luminal B breast cancer ( 4 ) , breast cancer, triple negative ( 4 ) , lung cancer ( 8 ) , non-small cell lung cancer ( 8 ) , melanoma skin cancer ( 3 ) , thyroid cancer ( 2 )
Relevant cell line - cell type - tissue:
'stem, embryonic' ( 13 ) , A375 (melanocyte) ( 3 ) , brain ( 1 ) , breast ( 4 , 7 ) , H2077 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC1359 (pulmonary) ( 8 ) , HCC4006 (pulmonary) ( 8 ) , HEK293T (epithelial) ( 3 ) , HeLa (cervical) ( 6 , 10 , 11 , 12 , 15 ) , HSJD-DIPG-007 ( 1 ) , LOU-NH91 (squamous) ( 8 ) , MV4-11 (macrophage) ( 14 ) , NCI-H1395 (pulmonary) ( 8 ) , NCI-H2030 (pulmonary) ( 8 ) , NCI-H460 (pulmonary) ( 8 ) , NSC H3.3-K27M ( 1 ) , SF8628 ( 1 ) , SK-MEL5 (melanocyte) ( 3 ) , SU-DIPG-13p ( 1 ) , SU-DIPG-VI (glial) ( 1 ) , SU-DIPGIV ( 1 )

Upstream Regulation
Regulatory protein:
BRAF (human) ( 3 ) , MEK5 (human) ( 3 )
Putative in vivo kinases:
ERK1 (human) ( 5 ) , ERK2 (human) ( 5 ) , ERK5 (human) ( 1 , 5 )
Kinases, in vitro:
ERK5 (human) ( 16 )
Treatments:
doxycycline ( 1 ) , EGF ( 5 , 12 ) , ERK5-IN-1 ( 1 ) , ischemia ( 7 ) , NGF ( 5 ) , nocodazole ( 11 ) , RO-3306 ( 3 ) , SB202190 ( 12 ) , SCH772984 ( 3 ) , sorbitol ( 11 ) , TG02 ( 1 ) , U0126 ( 5 , 12 ) , XMD17-109 ( 1 )

Downstream Regulation
Effects of modification on ERK5:
enzymatic activity, induced ( 1 ) , enzymatic activity, inhibited ( 11 ) , intracellular localization ( 2 , 3 , 5 , 11 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
apoptosis, inhibited ( 1 ) , cell growth, induced ( 1 ) , transcription, altered ( 11 ) , transcription, induced ( 1 , 2 , 3 , 5 )

Disease / Diagnostics Relevance
Relevant diseases:
glioma ( 1 )

References 

1

Koncar RF, et al. (2019) Identification of novel RAS signaling therapeutic vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Cancer Res
31201162   Curated Info

2

Ye F, et al. (2018) Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma. Int J Cancer
30132833   Curated Info

3

Tusa I, et al. (2018) ERK5 is activated by oncogenic BRAF and promotes melanoma growth. Oncogene
29483645   Curated Info

4

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

5

Honda T, et al. (2015) Phosphorylation of ERK5 on Thr732 Is Associated with ERK5 Nuclear Localization and ERK5-Dependent Transcription. PLoS One 10, e0117914
25689862   Curated Info

6

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

7

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

8

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

9

Gilley R, et al. (2012) CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIM(EL). Cell Signal 24, 170-80
21924351   Curated Info

10

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

11

IƱesta-Vaquera FA, et al. (2010) Alternative ERK5 regulation by phosphorylation during the cell cycle. Cell Signal 22, 1829-37
20667468   Curated Info

12

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

13

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

14

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

15

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

16

Mody N, et al. (2003) An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. Biochem J 372, 567-75
12628002   Curated Info